For heavily treatment-experienced adults with HIV-1 failing therapy. See Full Indication.
Access the resources below for additional details about RUKOBIA, including the challenges of people living with multidrug-resistant (MDR) HIV-1 who are failing their current therapy, its mechanism of action, information about the BRIGHTE trial, dosing and drug interactions, and the full Prescribing Information.
BRIGHTE Long-Term Data for RUKOBIA
~5-Year* Efficacy Results
Hear from Dr. Tony Mills on the exciting long-term data for RUKOBIA
BRIGHTE Educational Series
INTRODUCTION TO PEOPLE LIVING WITH MDR HIV-1
Consider challenges faced by people living with multidrug-resistant (MDR) HIV-1 with multidrug resistance and limited antiretroviral (ARV) options
NOVEL MECHANISM OF ACTION
Discover a first-in-class attachment inhibitor that prevents HIV-1 from interacting with host immune cells1
DOSING AND DRUG INTERACTIONS
Review recommended dosing, considerations for coadministration, and contraindications with RUKOBIA
Downloadable Resource
RUKOBIA PRESCRIBING INFORMATION
See the full Prescribing Information for RUKOBIA
References:
- Cahn P, Fink V, Patterson P. Fostemsavir: a new CD4 attachment inhibitor. Curr Opin HIV AIDS. 2018;13(4):341-345.
FSTWCNT230016